Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — Merger or Acquisition (October 2023)
14 slides from Kyowa Kirin's merger presentation, Oct 5, 2023
Slide 1: Agreement to acquire shares of Orchard Therapeutics
Agreement to acquire shares of Orchard Therapeutics
Slide 2: Forward-looking statements disclaimer
This document contains certain forward-looking statements relating to such items as the company’s (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward-looking statements are based upon information available to the company at the present time and upon reasona
Slide 3: Agenda
Agenda Agreement to acquire shares of Orchard Therapeutics Director of the Board, Senior Managing Executive officer and Chief Medical Officer Takeyoshi Yamashita, Ph.D. Q&A Director of the Board, Senior Managing Executive officer and Chief Medical OfficerTakeyoshi Yamashita, Ph.D. Managing Executive
Slide 4: Transaction Summary
Transaction Summary Items Summary ◼ Orchard Therapeutics plc (London) Target — Listed on NASDAQ ◼ $16.00 per ADS / approx. $387.4 million (approx. JPY 57.3 billion) — Orchard shareholders will hold additional contingent value rights (CVR) of $1.00 per ADS. Purchase Price* — Additional $1.00 CVR will
Slide 5: Strategic Rationale of The Transaction
Strategic Rationale of The Transaction Our purpose of the acquisition: ◼ To enrich our pipeline to address the UMNs* for which there is still no cure ◼ To obtain capabilities in Cell Gene * Therapy R&D to address the future UMNs * Unmet medical needs • Strengthen the business following Crysvita and
Slide 6: Overview of Orchard Therapeutics
Overview of Orchard Therapeutics Orchard Therapeutics plc Locations United Kingdom (HQ), United Sates, Netherlands, France, Italy, Germany, Switzerland, Sweden Business Biopharmaceutical company with specialty in Hematopoietic Stem Cell Gene Therapy (HSC-GT) Employees 166 employees (as of Dec. 2022)
Slide 7: What is Hematopoietic Stem Cell Gene Therapy (HSC-GT)? -1
What is Hematopoietic Stem Cell Gene Therapy (HSC-GT)? -1 Therapeutic HSC gene Brain Monocyte / High area of focus Macrophage GI Granulocyte Other Areas for potential Organ future T cells Integration Systems expansion B cells NK cells Megakaryocyte Self-renewal Erythrocyte HSC-GT allows delivery of
Slide 8: What is Hematopoietic Stem Cell Gene Therapy (HSC-GT)? -2
What is Hematopoietic Stem Cell Gene Therapy (HSC-GT)? -2 ◼ Treatment Process ◼ Durable Efficacy 1. Cells are collected from 1. 5. the patient 2. Blood stem cells are selected and purified 3. A working copy of the gene is inserted into the cells using a viral vector Gene-corrected cells are 2. froze
Slide 9: Libmeldy (OTL-200, atidarsagene autotemcel)
Libmeldy® (OTL-200, atidarsagene autotemcel) ◼ MLD (Metachromatic Leukodystrophy) ⚫ Fatal genetic CNS disorder ⚫ Rapid and irreversible loss of motor and cognitive function ⚫ In its most severe form, most children pass away within five years of symptom onset1 Ref.) Orchard Therapeutics plc, Q2 2023
Slide 10: Development Pipelines: OTL-203, OTL-201
Development Pipelines: OTL-203, OTL-201 OTL-203 OTL-201 ◼ Indication: MPS-IH1 ◼ Indication: MPS-IIIA 4 ⚫ Multisystemic neurometabolic condition affecting ⚫ Accumulation of substrate heparan sulfate leading to severe cognition, growth and skeletal function CNS degeneration w/ somatic manifestations ⚫
Slide 11: Expected Synergy
Expected Synergy Further Development as a Global Specialty Pharmaceutical Company ◼ To be a Japan-based Global Specialty Pharmaceutical Company providing life-changing value to high unmet medical needs in concert with our existing business through Crysvita and Poteligeo Reinforcement of New Drug Dis
Slide 12: Conclusion
Conclusion ◼ The acquisition of Orchard Therapeutics enables us to: - Enrich pipelines to address the UMNs for which there is still no cure - Gain capabilities in HSC-GT R&D to address the future UMNs - Delivery of Gene-Corrected Cells to Multiple Organ Systems - Durable efficacy, potential for “One
Slide 13: Kyowa Kirin Co., Ltd. Corporate Communications Dept., IR Group
Kyowa Kirin Co., Ltd. Corporate Communications Dept., IR Group +81-3-5205-7206 / ir@kyowakirin.com
Slide 14: Strategic Investment
Strategic Investment ～For successful creation and delivery of life-changing value Licensing-in and M&A investments to strengthen the portfolio ● Development pipeline with synergies with Crysvita 2021-2025 Cash Allocation* and Poteligeo ◆Bone, Mineral ◆Hematologic oncology ● Implementing the strength